Serum β-klotho is a potential biomarker in the prediction of clinical outcomes among patients with NSCLC.

ABSTRACT:

Background

We aimed to investigate the β-klotho (KLB) expression in non-small cell lung cancer (NSCLC) and to determine its value as a novel molecular target for survival prognosis in patients with NSCLC.

Methods

The serum KLB concentrations in 50 patients with NSCLC and the 20 healthy persons were measured by enzyme-linked immunosorbent assay (ELISA) methods. The relationship between serum KLB level, including the level change after therapy, and the progression-free survival (PFS) and overall survival (OS) were analyzed. The KLB expression in A549 cells was measured by real-time polymerase chain reaction (RT-PCR) and western blotting. The function of cells was revealed by in vitro studies.

Results

The concentrations of serum KLB in patients with NSCLC were obv

SUBMITTER: Zhou J 

PROVIDER: S-EPMC8182533 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature